Kaiser Permanente contributed to a round that pushed the total raised by the ceullar cancer therapy developer to $300m.
US-based cell therapy developer Orca Bio secured $192m on Wednesday in a series D round featuring healthcare provider Kaiser Permanente’s Group Trust as well as its Kaiser Foundation Hospitals subsidiary.
Venture capital firm Lightspeed Venture Partners co-led the round with an unnamed additional investor, while 8VC, Data Collective’s DCVC Bio unit, ND Capital, the Abu Dhabi-owned Mubadala Investment Company and Illinois Municipal Retirement Fund also took part.
Founded in 2016, Orca Bio is working on allogeneic cell therapies that will…
